The purpose of the study is to optimize survival by an adapted metabolic imaging therapy in patients with advances non-small cell lung cancer.
The primary objective of the study is to evaluate the role of SUV and metabolic volume measured by FDG PETScan in the early prediction of treatment response.
80 patients will be included in 2 years. They will be follow up for one year for monitoring the progression free survival.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age superior to 18 years old
Effective contraception method or negative pregnancy test at the inclusion
OMS inferior or equal to 1
Non-small cell lung cancer stage IIIb or IV
Non progressive disease after at lest 4 cycles of platinum-based chemotherapy
Eligible fo maintenance therapy with bevacizumab and/or pemetrexed
Inform consent signed
You may not be if
Evolution of a second cancer in the 3 years before inclusion
Pregnancy or breast-feeding
poorly controlled diabetes
curatorship or guardianship
contraindication to iodinated contrast agents
participation to another clinical research with an experimental drug
impossible decubitus
not possibility to follow-up the procedures of the study due to geographic, social or psychic reasons
